Final Program

52 SUNDAY • MAY 15
P60
P61
Facilitator:
P62
P63
P64
P65
P66
of Desloratadine in Japanese Patients with Seasonal Allergic
Rhinitis/S. Hisada, Y. Maeda, N. Oshima, Y. Tanaka, C.I.
Weinstein, K. Okubo, Tokyo, Japan, p.A1393
Clinical Implication of Adenosine Triphosphate in Sputum in
Asthma/T. Soma, T. Kobayashi, K. Nakagome, M. Nagata,
Saitama, Japan, p.A1394
Functional Antibody Deficiency in Chronic Lung Disease/R.M.
Trafford, V. Moffat, T. Brockley, C. Pantin, M. Babores, S. Iyer,
Macclesfield, United Kingdom, p.A1395
A. Yokoyama, MD, PhD, Kochi, Japan
Responder Rate Analysis of Asthma Control Questionnaire
Scores in Patients Treated with Once-Daily Fluticasone
Furoate/ Vilanterol or Fluticasone Furoate/C. Poor, S. Faison, L.
Sutton, D. Stempel, Research Triangle Park, NC, p.A1396
Impact of Irreversible Airflow Obstruction in Clinical Course of
Patients with Severe Atopic Asthma/K. Orimo, K. Takeyama, E.
Tagaya, M. Kondo, J. Tamaoki, Tokyo, Japan, p.A1397
Exploring Asthma Patients for Whom Switching to
Formoterol/Fluticasone Is Recommendable Among Patients
Inadequately Controlled with Salmeterol/Fluticasone/T. Kamei,
K. Kato, H. Mizutani, M. Hayashi, N. Kihara, Takamatsu, Japan,
p.A1398
Development of a Questionnaire to Evaluate Asthma Control in
Japanese Asthma Patients: A Pilot Study/S. Hozawa, H.
Tanaka, F. Mori, Y. Tohda, Hiroshima, Japan, p.A1399
Short-Term Effectiveness of Bronchial Thermoplasty on
Quality of Life and Control in Patients with Severe Asthma/K.
Kobayashi, M. Iikura, A. Shiozawa, I. Takazawa, S. Yamamoto, H.
Kawamoto, S. Ro, S. Ishii, S. Izumi, M. Hojo, H. Sugiyama, Tokyo,
Japan, p.A1400
P67 Does Asthma Phenotype Have Impact on Disease Control -
Can Detection of Inflammation and Hyperresponsiveness
Ensure Stable Disease Faster (APERITIF)?/K.F. Bernholm, A.-S.,
Homøe, H. Meteran, C. Porsbjerg, V. Backer, Copenhagen,
Denmark, p.A1401
P68
P69
P70
Facilitator:
P71
P72
Optimal Sampling Designs for Studies of Multiple Flow Exhaled
Nitric Oxide/S.P. Eckel, N. Molshatski, Los Angeles, CA, p.A1402
Allergic Bronchopulmonary Aspergillosis in South Asia with
Special Reference to Indian Children: The Demographic and
Clinical Presentation/M. Singh, N. Paul, A. Chauhan, K.S. Sodhi,
A. Chakrabarti, Chandigarh, India, p.A1403
Prevalence of Allergic Diseases in Children Living in Rural and
Urban Areas in Turkey/Y. Gokdemir, E. Civelek, B. Cakir, A.
Demir, C.N. Kocabas, R. Ersu, Istanbul, Turkey, p.A1404
J.G. Zein, MD, Cleveland, OH
Reduction in FeNO Is Correlated with FEV1 Improvement in
Lebrikizumab Treated Asthma Patients/F. Cai, Y. Zheng, C.
Holweg, D. Choy, J. Olsson, J. Matthews, H. Schereens, South San
Francisco, CA, p.A1405
Efficacy and Safety of Tratinterol Hydrochloride Tablets in
Bronchial Asthma: A Randomized, Double-Blind and
Multicenter Clinical Trial/L. Kong, J. Kang, Y. Zhao, Shenyang,
China, p.A1406
P73
P74
P75
P76
P77
P78
P79
P80
P81
A37
Clinical Effectiveness of Omalizumab in Severe Allergic
Asthma Above the Recommended Dosing Range: The
Australian Xolair Registry/M. Hew, A. Gillman, M. Sutherland, P.
Wark, J. Bowden, V. McDonald, M. Guo, H. Reddel, C. Jenkins, G.
Marks, J. Upham, F. Thien, J. Rimmer, G.P. Katsoulotos, M. Cook,
I. Yang, C. Katelaris, S. Bowler, D. Langton, P.G. Gibson, P.D.
Robinson, C. Wright, M. Bint, V. Yozghatlian, S. Burgess, P.
Sivakumaran, A. Jaffe, K. Yan, M. Peters, V. Kritikos, M. Baraket,
A. Aminazad, Melbourne, Australia, p.A1408
A Phase IIb Dose-Finding Study to Assess the Efficacy and
Safety of QAW039 (Fevipiprant) in Patients with Allergic
Asthma Uncontrolled on Low-Dose ICS Therapy/E.D. Bateman,
A.M. Mesquita, A.G. Guerreros, F. Brockhaus, B. Holzhauer, A.
Pethe, R.A. Kay, R.G. Townley, Cape Town, South Africa, p.A1408
Airway Eosinophilic Inflammation Assessed by Induced
Sputum and Blood IgE In Asthmatic Children/M. Ghezzi, A.
Kantar, Ponte San Pietro, Italy, p.A1409
The Effects of Low- and High- Expression of Brain-Derived
Neurotrophic Factor on the Intensity of Psychopathological
Variables in Asthma Patients: A Preliminary Report/M.G.
Panek, J. Ziolo, M. Jonakowski, T. Pietras, A. Antczak, J. Szemraj,
P. Kuna, Lodz, Poland, p.A1410
Reduction of Systemic Corticosteroid Requirement for Severe
Asthma Following Minimally-Invasive Nissen Fundoplication
for Severe GERD/S. Patel, A.K. Mathur, C. Galvani, T.F. Carr,
Tucson, AZ, p.A1411
House Dust Mite Sensitization as a Risk Factor for Exacerbation
of Asthma in the Fall/H.H. Kim, J.-S. Yoon, Y.H. Chun, H.S. Kim,
Uijeongbu-si, Gyeonggi-do, Korea, Republic of, p.A1412
Gender-Specific Effect of Overweight and Obesity on Total
Serum IgE in Adults with Allergic Asthma/M. Imaoka, Fukuoka,
Japan, p.A7776
The Potential Association between Adipocytokine and Steroid
Insensitivity in Obese Asthmatic Patients/M. To, N. Ogura, S.
Mikami, S. Soeda, H. Hara, N. Honda, A. Hitani, I. Kano, K. Haruki,
Y. To, Saitama, Japan, p.A7777
Clinical Characteristics of Obese Asthmatic Patients: Obese
Asthmatic Patients Need More Frequent Unscheduled Visits
and Rescue Uses of Corticosteroids/M. To, N. Ogura, S. Mikami,
S. Soeda, H. Hara, N. Honda, A. Hitani, I. Kano, K. Haruki, Y. To,
Saitama, Japan, p.A7778
THEMATIC POSTER SESSION
CYSTIC FIBROSIS: IMMUNE REGULATORY
PATHWAYS
9:00 a.m. - 4:15 p.m. MOSCONE CENTER
Viewing: Posters will be on display for entire session.
Area G, Hall D (North Building, Lower Level)
Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators
ATS 2016 • San Francisco